Data strengthen Topotarget’s BELIEF in lymphoma drug
This article was originally published in Scrip
Executive Summary
Latest topline data suggest Topotarget's earlier enthusiasm for its HDAC inhibitor belinostat in peripheral T-cell lymphoma (PTCL) was warranted. Data from the BELIEF trial suggests its efficacy is at least similar to that seen with two other drugs approved for PTCL in recent years and it has a better safety profile.